Oncoquest is under clinical development by XEME BioPharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Oncoquest’s likelihood of approval (LoA) and phase transition for Follicular Lymphoma took place on 11 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Oncoquest Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Oncoquest overview

Oncoquest vaccine is under development for the treatment of non-Hodgkin’s follicular lymphoma, solid tumours like lung cancer and colorectal cancer, platinum-resistant and relapsed ovarian cancer, prostate cancer, haematological malignancies including multiple myeloma and acute myeloid leukaemia, chronic lymphocytic leukaemia. The vaccine candidate is administered through subcutaneous route. It consists of patient-specific membrane proteins directly extracted from autologous tumour cells and incorporated into liposomes along with interleukin 2 (IL-2). The vaccine candidate is developed based on AGGREGON technology.

Quick View Oncoquest LOA Data

Report Segments
  • Innovator
Drug Name
  • Oncoquest
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.